NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · IEX Real-Time Price · USD
0.0756
-0.0017 (-2.20%)
Apr 25, 2024, 9:37 AM EDT - Market open
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NBY.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NBY.
Recommendation Trends
| Rating | Mar '22 | Apr '22 | May '22 |
|---|---|---|---|
| Strong Buy | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $149 → $140 | Strong Buy | Maintains | $149 → $140 | +185,085.19% | May 20, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2018 |
Financial Forecast
Revenue This Year
16.27M
from 14.73M
Increased by 10.45%
Revenue Next Year
21.79M
from 16.27M
Increased by 33.96%
EPS This Year
-0.41
from -3.96
EPS Next Year
0.07
from -0.41
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 16.9M | 22.7M |
| Avg | 16.3M | 21.8M |
| Low | 15.8M | 21.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 14.8% | 39.3% |
| Avg | 10.5% | 34.0% |
| Low | 7.2% | 30.0% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -0.43 | 0.07 |
| Avg | -0.41 | 0.07 |
| Low | -0.40 | 0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.